statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Bitcoin

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Invesco QQQ Trust Series 1

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Sage Therapeutics, Inc. (Nasdaq: SAGE), a biopharmaceutical company leading the way to create a world with better brain health, today reported business highlights and financial results for the first...

Sage Therapeutics Announces First Quarter 2024 Financial Results and Highlights Pipeline and Business Progress

Sage Therapeutics, Inc. (Nasdaq: SAGE) announced today topline results from PRECEDENT, a double-blind, placebo-controlled Phase 2 study of the investigational oral medicine dalzanemdor (SAGE-718) in...

Sage Therapeutics Announces Topline Results from Phase 2 PRECEDENT Study of Dalzanemdor (SAGE-718) in the Treatment of Mild Cognitive Impairment in Parkinsons Disease

Sage Therapeutics, Inc. (NASDAQ: SAGE), a biopharmaceutical company leading the way to create a world with better brain health, today announced that it will host a live webcast on Thursday, April 25...

Sage Therapeutics to Report First Quarter 2024 Financial Results on Thursday, April 25, 2024

This price move could be a signal that SAGE may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options...

Sage Therapeutics (SAGE, $17.91) price may climb as it broke lower Bollinger Band on Apr 01, 2024

This is a signal that SAGE's price could be shifting from a downtrend to an uptrend. Traders may consider buying the stock or exploring call options...

Sage Therapeutics (SAGE, $17.91) RSI Indicator left the oversold zone on April 01, 2024

Sage Therapeutics (NASDAQ:SAGE - Free Report) had its target price lifted by JPMorgan Chase  Co. from $24.00 to $29.00 in a research report report published on Tuesday, Benzinga reports. The...

Sage Therapeutics (NASDAQ:SAGE) Price Target Raised to $29.00

See the rest of the story here.

thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...

Sage Therapeutics management to meet with Piper Sandler

Sage Therapeutics (SAGE, $19.07) RSI Indicator left the oversold zone on March 27, 2024

Sage Therapeutics (SAGE, $19.71) RSI Indicator left the oversold zone on March 20, 2024

Sage Therapeutics (SAGE, $19.37) RSI Indicator left the oversold zone on March 18, 2024

SAGE Therapeutics, Inc. is a biopharmaceutical company, which engages in providing solutions to brain health medicines. It focuses on diseases and disorders of the brain. Its products include ZURZUVAE and ZULRESSO. The company was founded by Steven Marc Paul and Douglas Covey on April 16, 2010 and is headquartered in Cambridge, MA.

Volume	1.49M
52-Wk High	$59.99
52-Wk Low	$10.92

SAGE Sage Therapeutics Inc

About

Feed

News

Sentiment

Earnings

Fundamentals